MANAFEST – A novel sensitive, specific, scalable and simple method to identify functional anti-tumor T cell responses

Case ID:
C14390
Disclosure Date:
10/3/2016
Description:
Unmet Need
With the growth of cancer immunotherapy dependent on enhancing anti-tumor T cell responses, it has become important to rapidly, sensitively and specifically assess functional anti-tumor T cell responses, specifically via liquid biopsy.   Such biomarkers can define which patients will respond to a given immunotherapy and who might require additional therapies.  ELISPOT currently is used for this purpose, however ELISPOT lacks sensitivity and only assays cytokine production. 

Technology Overview
The technology is a novel, sensitive, specific, and scalable method to evaluate candidate tumor neoantigens for their ability to induce T cell responses.  This method could be broadly useful for functional evaluation of neo-antigens in research and clinical settings, including for biomarker prediction in checkpoint blockade therapy, and for identification of functional mutation-associated neoantigens for personalized immunotherapeutic approaches.
 
Patent Information:
Title App Type Country Serial No. Patent No. File Date Issued Date Expire Date Patent Status
MANAFEST – A novel sensitive, specific, scalable and simple method to identify functional anti-tumor T cell responses PCT: Patent Cooperation Treaty PCT PCT/US2017/056557   10/13/2017     Pending
Inventors:
Category(s):
For Information, Contact:
Jeanine Pennington
jpennin5@jhmi.edu
410-614-0300
Save This Technology:
2017 © Johns Hopkins Technology Ventures. All Rights Reserved. Powered by Inteum